Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{188299,
        author = {Ms. Krupa Mansukhbhai Badava and Sheth Nancy Rajendra and Ayushi Ajitsinh Rathod and Vaidik Patel},
        title = {Beyond The Ache: Aspirin’s Journey as the Repurposed Wonder Drug across the Therapeutic Domains},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {7},
        pages = {1390-1397},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=188299},
        abstract = {Acetylsalicylic acid, also known as aspirin, is a cheap medication that has been around for a century and has a strong pharmacology and safety record. Aspirin's repurposing, especially in the prevention of colorectal cancer and as an adjuvant across various tumors, is supported by growing mechanistic, epidemiologic, and clinical evidence beyond its use in analgesia and antiplatelet indications. It also suggests roles in immunomodulation, metastasis suppression, and metabolic/inflammatory disorders. The main clinical findings (prevention, adjuvant use, biomarker-guided benefit), translational strategies (computational screens, phenotypic assays, real-world data, and randomized trials), safety and regulatory issues, evidence, ongoing trials, safety and regulatory considerations, and practical future directions for aspirin repurposing across clinical domains are all summarized in this review. Even if the evidence is encouraging, before new indications are routinely used, thorough biomarker-guided randomized trials and consideration of bleeding risk, dosage, and patient selection are crucial.},
        keywords = {Aspirin, Acetylsalicylic acid, Antiplatelet therapy, Cyclooxygenase inhibition, Cancer chemoprevention, cardiovascular disease prevention, Clinical trials and Real-world evidence, Drug repurposing, Drug repositioning, Dose optimization, Metastasis suppression, NSAIDS, Nanoparticle drug delivery, Neurodegenerative disorders, PIK3CA biomarker, Precision medicine.},
        month = {December},
        }